Get the Stockscreener App
2.29
2.23%
0.05
After Hours:
2.33
0.04
+1.75%
Autolus Therapeutics Plc Adr stock is traded at $2.29, with a volume of 2.59M.
It is up +2.23% in the last 24 hours and down -18.21% over the past month.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
See More
Previous Close:
$2.24
Open:
$2.23
24h Volume:
2.59M
Relative Volume:
1.55
Market Cap:
$609.42M
Revenue:
-
Net Income/Loss:
$-208.38M
P/E Ratio:
-1.9244
EPS:
-1.19
Net Cash Flow:
$-156.57M
1W Performance:
-8.03%
1M Performance:
-18.21%
6M Performance:
-40.67%
1Y Performance:
-58.36%
1-Day Range:
$2.20
$2.35
1-Week Range:
$2.20
$2.6591
52-Week Range:
$2.20
$7.45
Autolus Therapeutics Plc Adr Stock (AUTL) Company Profile
Name
Autolus Therapeutics Plc Adr
Sector
Industry
Phone
44 20 3829 6230
Address
THE MEDIAWORKS, LONDON
Compare AUTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUTL
Autolus Therapeutics Plc Adr
|
2.29 | 609.42M | 0 | -208.38M | -156.57M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Autolus Therapeutics Plc Adr Stock (AUTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Upgrade | Goldman | Neutral → Buy |
| Nov-15-24 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Mar-27-23 | Resumed | Wells Fargo | Overweight |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Jun-14-21 | Upgrade | Jefferies | Hold → Buy |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | JP Morgan | Overweight |
| Jul-22-20 | Initiated | SunTrust | Buy |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Sep-23-19 | Initiated | Needham | Buy |
| May-17-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-24-18 | Initiated | H.C. Wainwright | Buy |
View All
Autolus Therapeutics Plc Adr Stock (AUTL) Latest News
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 - GlobeNewswire Inc.
MicroAlgo Inc’s (MLGO) -2.91% Drop Is A Reason To Reconsider. - Stocks Register
Aspen Aerogels Inc (ASPN) Strikes $14.34: The Risk Seems Worthwhile At This Price - Stocks Register
Autolus reports high response in leukemia study - Investing.com India
CommScope Holding Company Inc (COMM) Is A Good Investment At Current Valuations - Stocks Register
Autolus Therapeutics plc ADR (AUTL) Has A Gold Mine On Its Hands - Stocks Register
These Numbers Prove Just How Vibrant The Ocugen Inc (NASDAQ: OCGN) Stock Has Been - Stocks Register
Autolus stock upgraded as obe-cel approval drives optimism for commercial potential - Investing.com
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - Barchart
Does MP Materials Corporation (NYSE: MP) Still Need To Convince Analysts? - Stocks Register
Hafnia Ltd (NYSE: HAFN) Drops -3.00%, Turning Investors Away - Stocks Register
Autolus Therapeutics (AUTL): High-Growth UK Stock in Cancer Therapy - Yahoo Finance
Why Autolus Therapeutics plc (AUTL) is the Penny Stock with the Biggest Upside Potential According to Analysts - Yahoo Finance
PDD Holdings Inc ADR (NASDAQ: PDD) Has Been Trading Down. What Are The Prospects For The Future? - Stocks Register
What Do Wall Street Analysts Think About Moderna Inc (NASDAQ: MRNA) Stock? - Stocks Register
Before You Invest, Make Sure You Check This Autolus Therapeutics plc ADR (NASDAQ: AUTL) Analysis - Stocks Register
Autolus Therapeutics plc ADR (AUTL)’s stock rises to 4.14 per share - US Post News
Autolus Therapeutics plc ADR: -44.83% Growth from 52-Week Low, Yet Analysts Divided - The InvestChronicle
A better buy-in window may exist right now for Autolus Therapeutics plc ADR (AUTL) - SETE News
Upward Trajectory: Autolus Therapeutics plc ADR (AUTL) Posts a Slidee, Closing at 3.98 - The Dwinnex
Autolus Therapeutics plc ADR (AUTL) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Are Smart Investors Making the Right Decision? Autolus Therapeutics plc ADR (AUTL) - SETE News
Autolus Therapeutics plc ADR (AUTL) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Autolus Therapeutics plc ADR (AUTL)’s stock chart: A technical perspective - US Post News
Stock Performance Spotlight: Autolus Therapeutics plc ADR (AUTL) Ends the Day at 3.63, Up by 4.31 - The Dwinnex
A look into Autolus Therapeutics plc ADR (AUTL)’s deeper side - SETE News
Are Autolus Therapeutics plc ADR (AUTL) shares a good deal now? - US Post News
Autolus Therapeutics plc ADR (AUTL)’s Market Momentum: Closing Strong at 3.73, Down -3.12 - The Dwinnex
Autolus Therapeutics (NASDAQ:AUTL) Shares Down 4.8% - MarketBeat
Autolus Therapeutics names new Chief Development Officer - Investing.com India
Autolus Therapeutics names new Chief Development Officer By Investing.com - Investing.com South Africa
Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Down 8.0% in August - Defense World
Autolus Therapeutics plc ADR (AUTL) looking to reclaim success with recent performance - SETE News
Autolus Therapeutics plc ADR (AUTL) Stock: Navigating a Year of Volatility - The InvestChronicle
Autolus Therapeutics plc (NASDAQ:AUTL) Shares Acquired by Daiwa Securities Group Inc. - Defense World
Autolus Therapeutics plc ADR (AUTL)’s stock price in review: A technical analysis - US Post News
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $4.08 - MarketBeat
Financial Metrics Check: Autolus Therapeutics plc ADR (AUTL)’s Ratios for Trailing Twelve Months - The Dwinnex
Autolus secures £18.5M for facility upgrades - Investing.com
Autolus Therapeutics plc ADR (AUTL) is looking forward to a strong quarter - SETE News
Trading Day Review: Autolus Therapeutics plc ADR (AUTL) Gains Momentum, Closing at 4.12 - The Dwinnex
Autolus Therapeutics plc ADR (AUTL) presents a great opportunity, but the stock is slightly overvalued - US Post News
Autolus Therapeutics (NASDAQ:AUTL) Stock Price Up 6% - MarketBeat
Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 3.4% - MarketBeat
It is Poised to be a Bull Market for Autolus Therapeutics plc ADR (AUTL) - SETE News
Contrasting Autolus Therapeutics (NASDAQ:AUTL) & ZIVO Bioscience (NASDAQ:ZIVO) - Defense World
Autolus reports promising results for obe-cel in leukemia study - Investing.com India
Views of Wall Street’s Leading Experts on Autolus Therapeutics plc ADR - SETE News
Is Autolus Therapeutics plc ADR (AUTL) a good investment opportunity? - US Post News
SG Americas Securities LLC Purchases 169,387 Shares of Autolus Therapeutics plc (NASDAQ:AUTL) - Defense World
Take off with Autolus Therapeutics plc ADR (AUTL): Get ready for trading - SETE News
Autolus Therapeutics Plc Adr Stock (AUTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):